IgA Nephropathy clinical trials at UCSF
2 in progress, 0 open to eligible people
Showing trials for
Atrasentan in Patients With IgA Nephropathy
Sorry, in progress, not accepting new patients
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
San Francisco, California and other locations
Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sorry, not yet accepting patients
The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.
San Francisco, California and other locations
Last updated: